RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can ...

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory syncytial ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five ...

Newer formulations are even more effective at preventing illnesses that commonly afflict seniors — perhaps even dementia.

A prominent paediatrician on Sunday urged people to take more precautions against a common virus known as RSV, saying cases ...

The FDA has approved clesrovimab, marketed as Enflonsia, for the prevention of RSV lower respiratory tract disease in ...

In advance of this week's CDC vaccine advisory meeting, HHS Secretary Robert F. Kennedy Jr. restacked the committee, claiming ...

A scientist in charge of Covid-19 and respiratory syncytial virus data has abruptly resigned, telling colleagues she doesn’t ...

A senior scientist at the US CDC has resigned, warning that changes in leadership may weaken the country’s vaccine program.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.